Login to Your Account

Actelion shares climb as selexipag aces phase III trial

By Cormac Sheridan
Staff Writer

Monday, June 16, 2014
Shares in Actelion Ltd. rose 15 percent during trading Monday on news that selexipag, its first-in-class selective oral prostacyclin IP receptor agonist, met the primary endpoint of a phase III outcomes trial in 1,156 patients with pulmonary arterial hypertension (PAH). Those on the drug had a 39 percent reduction in risk of experiencing a morbidity or mortality event vs. those on placebo. The result was highly statistically significant (p < 0.0001).

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription